Research programme: endocannabinoid reuptake inhibitors - Synendos Therapeutics/University of Bern
Latest Information Update: 23 Nov 2020
At a glance
- Originator NCCR TransCure; University of Bern
- Developer University of Bern
- Class Anxiolytics; Mood stabilisers; Small molecules
- Mechanism of Action Anandamide reuptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Anxiety disorders; Mood disorders; Traumatic stress disorders
Most Recent Events
- 13 Nov 2020 Preclinical trials in Mood disorders in Switzerland, prior November 2020
- 13 Nov 2020 Preclinical trials in Traumatic stress disorders in Switzerland, prior November 2020